TP53 and acute myeloid leukemia: This mutation is expressed in up to 50% of AML [125,126].Therefore, there is significant interest in MDM2 antagonists as promising anticancer agents to block MDM2–p53 interactions and restore the tumor-suppressor functions of wild-type p53 [127,128].